We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.
- Recent SRPT Stock Price: $149.10
- Yearly Gain for SRPT stock: 111.54%
- Market Cap for SRPT stock: $13.64B
- P/E Ratio for SRPT stock: -11.539
Will SRPT's stock price go up? Is there an accurate SRPT stock forecast available?
TipRanks.com reports that Sarepta Therapeutics currently has 22 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $170.94. The target pricing ranges from a high SRPT forecast of $206.00 down to a low forecast of $138.00. Sarepta Therapeutics (SRPT)’s last closing stock price was $149.10 which would put the average price target at 18.38% upside.
In addition, TradingView issued a Buy rating for SRPT stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on SRPT stock.
Other analysts covering SRPT include:
- Brian Abrahams of RBC Capital issued a Buy rating with the price target of $ 218 on 3 days ago
- Tazeen Ahmad of Bank of America Securities issued a Buy rating with the price target of $ 176 on 4 days ago
- Judah Frommer of Credit Suisse issued a Hold rating with the price target of $ 151 on 4 days ago
- Neena Bitritto-Garg of Citi issued a Buy rating with the price target of $ 204 on 4 days ago
If you are wondering if SRPT is a good stock to buy, here are 3rd party ratings for SRPT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 45% (114 out of 251)
What is the sentiment on the street regarding Sarepta Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for SRPT stock: Very Bullish
- Blogger Consensus for SRPT stock: Bullish
- Media Buzz for SRPT stock: High
- Insider Signal for SRPT stock: ―
- Investor Sentiment for SRPT stock: Very Positive
- Hedge Fund signal for SRPT stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on SRPT stock including scouring the social networks like SRPT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SRPT stock chart >>
Summary: UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
- Recent QURE Stock Price: $21.27
- Yearly Gain for QURE stock: 54.51%
- Market Cap for QURE stock: $985.94M
- P/E Ratio for QURE stock: -6.197
Will QURE's stock price go up? Is there an accurate QURE stock forecast available?
TipRanks.com reports that uniQure currently has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $56.11. The target pricing ranges from a high QURE forecast of $90.00 down to a low forecast of $38.00. uniQure (QURE)’s last closing stock price was $21.27 which would put the average price target at 153.88% upside.
In addition, TradingView issued a Buy rating for QURE stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on QURE stock.
Other analysts covering QURE include:
- Danielle Brill of Raymond James issued a Buy rating with the price target of $ 56 on 3 days ago
- Patrick Trucchio of H.C. Wainwright issued a Buy rating with the price target of $ 90 on 3 days ago
- Matthew Barcus of Chardan Capital issued a Buy rating with the price target of $ 45 on 4 days ago
If you are wondering if QURE is a good stock to buy, here are 3rd party ratings for QURE stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 45% (114 out of 251)
What is the sentiment on the street regarding uniQure? (Current ratings compiled by TipRanks.com)
- News Sentiment for QURE stock: Very Bullish
- Blogger Consensus for QURE stock: Bullish
- Media Buzz for QURE stock: High
- Insider Signal for QURE stock: Very Negative
- Investor Sentiment for QURE stock: Neutral
- Hedge Fund signal for QURE stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on QURE stock including scouring the social networks like QURE StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for QURE stock chart >>
Summary: Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
- Recent TEVA Stock Price: $7.91
- Yearly Gain for TEVA stock: -0.60%
- Market Cap for TEVA stock: $9.51B
- P/E Ratio for TEVA stock: -5.729
Will TEVA's stock price go up? Is there an accurate TEVA stock forecast available?
TipRanks.com reports that Teva Pharmaceutical currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $11.67. The target pricing ranges from a high TEVA forecast of $14.00 down to a low forecast of $10.00. Teva Pharmaceutical (TEVA)’s last closing stock price was $7.91 which would put the average price target at 58.03% upside.
In addition, TradingView issued a Strong Sell rating for TEVA stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on TEVA stock.
Other analysts covering TEVA include:
- Nathan Rich of Goldman Sachs issued a Hold rating with the price target of n/a on 1 day ago
- Jason Gerberry of Bank of America Securities issued a Buy rating with the price target of $ 11 on 1 day ago
- Unknown Analyst of Barclays issued a Buy rating with the price target of $ 14 on 1 week ago
If you are wondering if TEVA is a good stock to buy, here are 3rd party ratings for TEVA stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 49% (123 out of 251)
What is the sentiment on the street regarding Teva Pharmaceutical? (Current ratings compiled by TipRanks.com)
- News Sentiment for TEVA stock: Very Bullish
- Blogger Consensus for TEVA stock: Bullish
- Media Buzz for TEVA stock: Medium
- Insider Signal for TEVA stock: ―
- Investor Sentiment for TEVA stock: Positive
- Hedge Fund signal for TEVA stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on TEVA stock including scouring the social networks like TEVA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for TEVA stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
